

# Rajiv Jalan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6102952/publications.pdf>

Version: 2024-02-01

436  
papers

32,701  
citations

3530

90  
h-index

5120

166  
g-index

478  
all docs

478  
docs citations

478  
times ranked

17549  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1426-1437.e9.	1.3	2,211
2	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	1.3	1,840
3	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014, 61, 1038-1047.	3.7	741
4	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). <i>Hepatology International</i> , 2009, 3, 269-282.	4.2	709
5	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. <i>Journal of Hepatology</i> , 2014, 60, 1310-1324.	3.7	685
6	Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. <i>Journal of Hepatology</i> , 2015, 62, 968-974.	3.7	571
7	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264.	7.3	550
8	Acute-on chronic liver failure. <i>Journal of Hepatology</i> , 2012, 57, 1336-1348.	3.7	545
9	Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. <i>Hepatology</i> , 2015, 62, 243-252.	7.3	493
10	Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. <i>Journal of Hepatology</i> , 2004, 40, 247-254.	3.7	469
11	Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. <i>Hepatology</i> , 2013, 57, 1153-1162.	7.3	452
12	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , 2015, 64, 531-537.	12.1	405
13	Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. <i>Gut</i> , 2018, 67, 1870-1880.	12.1	375
14	Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. <i>Gut</i> , 2011, 60, 702-709.	12.1	359
15	Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, S131-S143.	3.7	358
16	A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2014, 146, 1231-1239.e6.	1.3	353
17	Acute-on-Chronic Liver Failure. <i>New England Journal of Medicine</i> , 2020, 382, 2137-2145.	27.0	353
18	Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. <i>Liver International</i> , 2008, 28, 767-780.	3.9	350

#	ARTICLE	IF	CITATIONS
19	Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure. <i>Lancet</i> , The, 1999, 354, 1164-1168.	13.7	346
20	Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. <i>Hepatology</i> , 2013, 58, 1836-1846.	7.3	327
21	Acute-on-chronic liver failure in cirrhosis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16041.	30.5	320
22	Targeting the gut-liver axis in liver disease. <i>Journal of Hepatology</i> , 2017, 67, 1084-1103.	3.7	311
23	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 831-840.	3.7	289
24	Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. <i>Hepatology</i> , 2007, 46, 831-840.	7.3	287
25	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282
26	Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: A randomized controlled study. <i>Liver Transplantation</i> , 2004, 10, 1109-1119.	2.4	272
27	Acute-on-chronic liver failure. <i>Lancet</i> , The, 2015, 386, 1576-1587.	13.7	270
28	Acute-on-Chronic Liver Failure: Pathophysiological Basis of Therapeutic Options. <i>Blood Purification</i> , 2002, 20, 252-261.	1.8	263
29	Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. <i>Journal of Hepatology</i> , 2008, 48, 945-951.	3.7	257
30	Toward an Improved Definition of Acute-on-Chronic Liver Failure. <i>Gastroenterology</i> , 2014, 147, 4-10.	1.3	255
31	Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. <i>Gastroenterology</i> , 2004, 127, 1338-1346.	1.3	252
32	Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. <i>Journal of Hepatology</i> , 2016, 64, 717-735.	3.7	243
33	Factors Associated with Survival of Patients With Severe Acute-On-Chronic Liver Failure Before and After Liver Transplantation. <i>Gastroenterology</i> , 2019, 156, 1381-1391.e3.	1.3	236
34	Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. <i>Hepatology</i> , 2012, 56, 1391-1400.	7.3	228
35	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. <i>Journal of Hepatology</i> , 2019, 70, 398-411.	3.7	225
36	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	3.7	223

#	ARTICLE	IF	CITATIONS
37	Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. <i>Journal of Hepatology</i> , 2003, 38, 419-425.	3.7	221
38	Role of ammonia and inflammation in minimal hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2007, 22, 125-138.	2.9	219
39	Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. <i>Journal of Hepatology</i> , 2020, 73, 1526-1547.	3.7	219
40	Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: A multicenter survey on safety and efficacy. <i>Hepatology</i> , 2013, 57, 2448-2457.	7.3	217
41	Intensive care of the patient with cirrhosis. <i>Hepatology</i> , 2011, 54, 1864-1872.	7.3	215
42	Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. <i>Hepatology</i> , 2009, 50, 555-564.	7.3	208
43	The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 670-685.	3.7	204
44	Relationship Between Activation of the Sympathetic Nervous System and Renal Blood Flow Autoregulation in Cirrhosis. <i>Gastroenterology</i> , 2008, 134, 111-119.e2.	1.3	202
45	Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 437-447.	3.7	196
46	Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2016, 64, 574-582.	3.7	196
47	Albumin in decompensated cirrhosis: new concepts and perspectives. <i>Gut</i> , 2020, 69, 1127-1138.	12.1	190
48	Pathogenesis of intracranial hypertension in acute liver failure: inflammation, ammonia and cerebral blood flow. <i>Journal of Hepatology</i> , 2004, 41, 613-620.	3.7	189
49	Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. <i>Hepatology</i> , 2002, 36, 1163-1171.	7.3	183
50	Endotoxemia produces coma and brain swelling in bile duct ligated rats. <i>Hepatology</i> , 2007, 45, 1517-1526.	7.3	182
51	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. <i>Gastroenterology</i> , 2019, 157, 149-162.	1.3	178
52	Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic protosystemic stent-shunt for variceal haemorrhage. <i>Journal of Hepatology</i> , 1995, 23, 123-128.	3.7	172
53	Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. <i>Journal of Hepatology</i> , 2003, 38, 24-31.	3.7	165
54	The pathophysiological basis of acute-on-chronic liver failure. <i>Liver</i> , 2002, 22, 5-13.	0.1	162

#	ARTICLE	IF	CITATIONS
55	Evaluation of coagulation abnormalities in acute liver failure. <i>Journal of Hepatology</i> , 2012, 57, 780-786.	3.7	160
56	Aromatic Amino Acid Metabolism during Liver Failure. <i>Journal of Nutrition</i> , 2007, 137, 1579S-1585S.	2.9	154
57	Evidence of neutrophil functional defect despite inflammation in stable cirrhosis. <i>Journal of Hepatology</i> , 2011, 55, 574-581.	3.7	154
58	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
59	Ammonia impairs neutrophil phagocytic function in liver disease. <i>Hepatology</i> , 2008, 48, 1202-1212.	7.3	139
60	Cirrhosis-associated immune dysfunction. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 112-134.	17.8	139
61	Albumin in chronic liver disease: structure, functions and therapeutic implications. <i>Hepatology International</i> , 2016, 10, 124-132.	4.2	137
62	Interorgan ammonia metabolism in liver failure. <i>Neurochemistry International</i> , 2002, 41, 177-188.	3.8	136
63	The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. <i>Journal of Hepatology</i> , 2011, 55, 1103-1111.	3.7	135
64	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	4.8	134
65	Moderate hypothermia prevents cerebral hyperemia and increase in intracranial pressure in patients undergoing liver transplantation for acute liver failure. <i>Transplantation</i> , 2003, 75, 2034-2039.	1.0	132
66	Hepatic encephalopathy: a critical current review. <i>Hepatology International</i> , 2018, 12, 135-147.	4.2	132
67	Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B.. <i>Scientific Reports</i> , 2016, 6, 25487.	3.3	125
68	Urea cycle dysregulation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018, 69, 905-915.	3.7	123
69	l-Ornithine phenylacetate (OP): A novel treatment for hyperammonemia and hepatic encephalopathy. <i>Medical Hypotheses</i> , 2007, 69, 1064-1069.	1.5	121
70	Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. <i>JHEP Reports</i> , 2020, 2, 100169.	4.9	120
71	Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. <i>Hepatology</i> , 2004, 39, 471-475.	7.3	118
72	Interorgan ammonia metabolism in liver failure: the basis of current and future therapies. <i>Liver International</i> , 2011, 31, 163-175.	3.9	118

#	ARTICLE	IF	CITATIONS
73	Acute-on-chronic liver failure in patients with alcohol-related liver disease. <i>Journal of Hepatology</i> , 2019, 70, 319-327.	3.7	117
74	Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. <i>Journal of Hepatology</i> , 2012, 56, 1047-1053.	3.7	114
75	Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. <i>Metabolic Brain Disease</i> , 2007, 22, 375-388.	2.9	113
76	Restoration of cerebral blood flow autoregulation and reactivity to carbon dioxide in acute liver failure by moderate hypothermia. <i>Hepatology</i> , 2001, 34, 50-54.	7.3	112
77	Protocols and Mechanisms for Remote Ischemic Preconditioning: A Novel Method for Reducing Ischemia Reperfusion Injury. <i>Transplantation</i> , 2007, 84, 445-458.	1.0	111
78	Validation of CLIF-C ACLF score to define a threshold for futility of intensive care support for patients with acute-on-chronic liver failure. <i>Critical Care</i> , 2018, 22, 254.	5.8	110
79	Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. <i>Gastroenterology</i> , 2000, 118, 565-572.	1.3	108
80	The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. <i>Hepatology</i> , 2003, 37, 1277-1285.	7.3	108
81	Inflammation and portal hypertension – The undiscovered country. <i>Journal of Hepatology</i> , 2014, 61, 155-163.	3.7	107
82	Intracranial Hypertension in Acute Liver Failure: Pathophysiological Basis of Rational Management. <i>Seminars in Liver Disease</i> , 2003, 23, 271-282.	3.6	106
83	Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. <i>Journal of Hepatology</i> , 2005, 43, 142-148.	3.7	106
84	Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. <i>Critical Care</i> , 2012, 16, R227.	5.8	105
85	Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. <i>Hepatology</i> , 2007, 45, 62-71.	7.3	103
86	Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. <i>Liver International</i> , 2013, 33, 398-409.	3.9	102
87	Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. <i>Liver Transplantation</i> , 2018, 24, 380-393.	2.4	101
88	Liver derived pro-inflammatory cytokines may be important in producing intracranial hypertension in acute liver failure. <i>Journal of Hepatology</i> , 2002, 37, 536-538.	3.7	100
89	Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis. <i>Hepatology</i> , 2003, 37, 931-939.	7.3	99
90	Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson's disease. <i>Liver Transplantation</i> , 2002, 8, 962-967.	2.4	98

#	ARTICLE	IF	CITATIONS
91	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). <i>Journal of Hepatology</i> , 2021, 75, 610-622.	3.7	96
92	Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure. <i>Journal of Hepatology</i> , 2020, 73, 102-112.	3.7	94
93	Sepsis in alcohol-related liver disease. <i>Journal of Hepatology</i> , 2017, 67, 1031-1050.	3.7	93
94	Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival. <i>Journal of Hepatology</i> , 2020, 72, 481-488.	3.7	93
95	Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis. <i>Liver International</i> , 2007, 27, 1194-1201.	3.9	90
96	Prognostic Role of Ammonia in Patients With Cirrhosis. <i>Hepatology</i> , 2019, 70, 982-994.	7.3	90
97	Interorgan ammonia trafficking in liver disease. <i>Metabolic Brain Disease</i> , 2009, 24, 169-181.	2.9	89
98	Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14â€œDay Waitlist Mortality Than Statusâ€œ1a Patients. <i>Hepatology</i> , 2019, 70, 334-345.	7.3	87
99	Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcoholâ€œrelated acuteâ€œchronic liver failure. <i>Liver International</i> , 2015, 35, 724-734.	3.9	85
100	AlfapumpÂ® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. <i>Journal of Hepatology</i> , 2017, 67, 940-949.	3.7	85
101	Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit?. <i>Kidney International</i> , 2017, 92, 1058-1070.	5.2	84
102	Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. <i>Clinical Science</i> , 2004, 106, 467-474.	4.3	83
103	The molecular pathogenesis of hepatic encephalopathy. <i>International Journal of Biochemistry and Cell Biology</i> , 2003, 35, 1175-1181.	2.8	82
104	Emerging Indications for Albumin Dialysis. <i>American Journal of Gastroenterology</i> , 2005, 100, 468-475.	0.4	82
105	Acute liver failure: current management and future prospects. <i>Journal of Hepatology</i> , 2005, 42, S115-S123.	3.7	81
106	Effect of albumin dialysis on intracranial pressure increase in pigs with acute liver failure: A randomized study*. <i>Critical Care Medicine</i> , 2006, 34, 158-164.	0.9	81
107	Beyond scoring: a modern interpretation of disease progression in chronic liver disease. <i>Gut</i> , 2013, 62, 1234-1241.	12.1	81
108	Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension. <i>Journal of Hepatology</i> , 2016, 64, 823-833.	3.7	80

#	ARTICLE	IF	CITATIONS
109	Orchestration of Tryptophanâ€Kynurenine Pathway, Acute Decompensation, and Acuteâ€onâ€Chronic Liver Failure in Cirrhosis. <i>Hepatology</i> , 2019, 69, 1686-1701.	7.3	80
110	L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats. <i>Hepatology</i> , 2009, 50, 155-164.	7.3	79
111	L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. <i>Hepatology</i> , 2009, 50, 165-174.	7.3	78
112	Primary graft dysfunction after liver transplantation: From pathogenesis to prevention. <i>Liver Transplantation</i> , 1997, 3, 137-148.	1.8	77
113	Equilibrium Contrast-enhanced CT Imaging to Evaluate Hepatic Fibrosis: Initial Validation by Comparison with Histopathologic Sampling. <i>Radiology</i> , 2015, 275, 136-143.	7.3	77
114	Acute-on-Chronic Liver Failure: Definition, Diagnosis, and Clinical Characteristics. <i>Seminars in Liver Disease</i> , 2016, 36, 109-116.	3.6	77
115	Cell death markers in patients with cirrhosis and acute decompensation. <i>Hepatology</i> , 2018, 67, 989-1002.	7.3	76
116	PROSPECTS FOR EXTRACORPOREAL LIVER SUPPORT. <i>Gut</i> , 2004, 53, 890-898.	12.1	75
117	Treatment of Phenytoin Toxicity by the Molecular Adsorbents Recirculating Systemâ€f(MARS). <i>Epilepsia</i> , 2003, 44, 265-267.	5.1	74
118	Pathophysiological basis of therapy of raised intracranial pressure in acute liver failure. <i>Neurochemistry International</i> , 2005, 47, 78-83.	3.8	74
119	Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 799-806.	3.7	73
120	Infection and inflammation in liver failure: Two sides of the same coin. <i>Journal of Hepatology</i> , 2009, 51, 426-429.	3.7	72
121	Hepatic encephalopathy and ascites. <i>Lancet, The</i> , 1997, 350, 1309-1315.	13.7	70
122	Albumin dialysis: a new therapeutic strategy for intoxication from protein-bound drugs. <i>Intensive Care Medicine</i> , 2004, 30, 496-501.	8.2	69
123	Ammonia and inflammation in the pathogenesis of hepatic encephalopathy: Pandora's box?. <i>Hepatology</i> , 2007, 46, 291-294.	7.3	67
124	Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. <i>Kidney International</i> , 2015, 87, 509-515.	5.2	67
125	Elevation of intracranial pressure following transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. <i>Journal of Hepatology</i> , 1997, 27, 928-933.	3.7	65
126	Ammonia and Hepatic Encephalopathy: The More Things Change, the More They Remain the Same. <i>Metabolic Brain Disease</i> , 2005, 20, 169-179.	2.9	65



#	ARTICLE	IF	CITATIONS
127	Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. <i>Liver Transplantation</i> , 2007, 13, 400-405.	2.4	65
128	Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. <i>Journal of Hepatology</i> , 2015, 62, 325-331.	3.7	65
129	Transjugular intrahepatic portosystemic stent-shunt (TIPSS) occlusion and the role of biliary venous fistulae. <i>Journal of Hepatology</i> , 1996, 24, 169-176.	3.7	63
130	Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 874-892.	7.3	62
131	Dispelling myths in the treatment of hepatic encephalopathy. <i>Lancet, The</i> , 2005, 365, 431-433.	13.7	62
132	Indocyanine green clearance reflects reperfusion injury following liver transplantation and is an early predictor of graft function. <i>Journal of Hepatology</i> , 1999, 30, 142-148.	3.7	61
133	Importance of Connexin-43 based gap junction in cirrhosis and acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2013, 58, 1194-1200.	3.7	61
134	Inhibition of glutamine synthetase in monocytes from patients with acute-on-chronic liver failure resuscitates their antibacterial and inflammatory capacity. <i>Gut</i> , 2019, 68, 1872-1883.	12.1	60
135	Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 617-625.	3.7	59
136	Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome. <i>Seminars in Nephrology</i> , 2019, 39, 17-30.	1.6	59
137	Paracetamol: are therapeutic doses entirely safe?. <i>Lancet, The</i> , 2006, 368, 2195-2196.	13.7	58
138	Role of aquaporin-4 in the development of brain oedema in liver failure. <i>Journal of Hepatology</i> , 2010, 53, 91-97.	3.7	56
139	Extracorporeal liver assist device to exchange albumin and remove endotoxin in acute liver failure: Results of a pivotal pre-clinical study. <i>Journal of Hepatology</i> , 2015, 63, 634-642.	3.7	56
140	Impaired brain glymphatic flow in experimental hepatic encephalopathy. <i>Journal of Hepatology</i> , 2019, 70, 40-49.	3.7	55
141	Isoleucine infusion during "simulated" upper gastrointestinal bleeding improves liver and muscle protein synthesis in cirrhotic patients. <i>Hepatology</i> , 2007, 45, 560-568.	7.3	54
142	Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 1063-1076.	3.9	53
143	Short chain fatty acids exchange: Is the cirrhotic, dysfunctional liver still able to clear them?. <i>Clinical Nutrition</i> , 2010, 29, 365-369.	5.0	52
144	Role of Toll-Like Receptor 4 in Mediating Multiorgan Dysfunction in Mice With Acetaminophen Induced Acute Liver Failure. <i>Liver Transplantation</i> , 2013, 19, 751-761.	2.4	52

#	ARTICLE	IF	CITATIONS
145	Clinical and Pathophysiological Characteristics of Cirrhotic Patients with Grade 1 and Minimal Hepatic Encephalopathy. <i>PLoS ONE</i> , 2016, 11, e0146076.	2.5	50
146	Role of ammonia, inflammation, and cerebral oxygenation in brain dysfunction of acuteâ€“chronic liver failure patients. <i>Liver Transplantation</i> , 2016, 22, 732-742.	2.4	50
147	Design, Analysis, and Pitfalls of Clinical Trials Using Ex Situ Liver Machine Perfusion: The International Liver Transplantation Society Consensus Guidelines. <i>Transplantation</i> , 2021, 105, 796-815.	1.0	50
148	Peripheral vascular tone in patients with cirrhosis: role of the reninâ€“angiotensin and sympathetic nervous systems. <i>Cardiovascular Research</i> , 1998, 38, 221-228.	3.8	49
149	Hemostasis in patients with acute kidney injury secondary to acute liver failure. <i>Kidney International</i> , 2013, 84, 158-163.	5.2	49
150	Albumin infusion improves renal blood flow autoregulation in patients with acute decompensation of cirrhosis and acute kidney injury. <i>Liver International</i> , 2015, 35, 335-343.	3.9	48
151	Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver. <i>Gut</i> , 2003, 52, 1041-1045.	12.1	47
152	Increased Gene and Protein Expression of the Novel eNOS Regulatory Protein NOSTRIN and a Variant in Alcoholic Hepatitis. <i>Gastroenterology</i> , 2007, 132, 2533-2541.	1.3	46
153	Liver Transplantation for Acuteâ€“Chronic Liver Failure: Science or Fiction?. <i>Liver Transplantation</i> , 2020, 26, 906-915.	2.4	46
154	Longterm Outcomes of Patients Undergoing Liver Transplantation for Acuteâ€“Chronic Liver Failure. <i>Liver Transplantation</i> , 2020, 26, 1594-1602.	2.4	46
155	Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. <i>Hepatology</i> , 2001, 33, 826-831.	7.3	45
156	Hyperammonemia and Systemic Inflammatory Response Syndrome Predicts Presence of Hepatic Encephalopathy in Dogs with Congenital Portosystemic Shunts. <i>PLoS ONE</i> , 2014, 9, e82303.	2.5	45
157	Dynamic Prognostication in Critically Ill Cirrhotic Patients With Multiorgan Failure in ICUs in Europe and North America: A Multicenter Analysis*. <i>Critical Care Medicine</i> , 2018, 46, 1783-1791.	0.9	45
158	Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. <i>Journal of Hepatology</i> , 2021, 74, 1117-1131.	3.7	45
159	Management of hepatic encephalopathy in patients with cirrhosis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 95-110.	2.4	44
160	A prospective evaluation of changes in neuropsychological and liver function tests following transjugular intrahepatic portosystemic stent-shunt. <i>Journal of Hepatology</i> , 1995, 23, 697-705.	3.7	43
161	The inflammatory basis of intracranial hypertension in acute liver failure. <i>Journal of Hepatology</i> , 2001, 34, 940-942.	3.7	43
162	Artificial Liver Support Systems in the Management of Complications of Cirrhosis. <i>Seminars in Liver Disease</i> , 2008, 28, 096-109.	3.6	43

#	ARTICLE	IF	CITATIONS
163	Prospective evaluation of haematological alterations following the transjugular intrahepatic portosystemic stent-shunt (TIPSS). <i>European Journal of Gastroenterology and Hepatology</i> , 1996, 8, 381-386.	1.6	42
164	Outpatient™ albumin dialysis for cholestatic patients with intractable pruritus. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 696-704.	3.7	42
165	Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. <i>Hepatology</i> , 2007, 47, 160-168.	7.3	41
166	Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats. <i>Liver International</i> , 2012, 32, 410-419.	3.9	39
167	Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G145-G152.	3.4	39
168	Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF. <i>Frontiers in Immunology</i> , 2020, 11, 619039.	4.8	39
169	Binding of bilirubin and bromosulphthalein to albumin: Implications for understanding the pathophysiology of liver failure and its management. <i>Liver Transplantation</i> , 2004, 10, 1531-1538.	2.4	38
170	Association of reduced extracellular brain ammonia, lactate, and intracranial pressure in pigs with acute liver failure. <i>Hepatology</i> , 2007, 46, 1883-1892.	7.3	38
171	Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats. <i>Journal of Hepatology</i> , 2014, 60, 545-553.	3.7	37
172	Oral amino acid load mimicking hemoglobin results in reduced regional cerebral perfusion and deterioration in memory tests in patients with cirrhosis of the liver. <i>Metabolic Brain Disease</i> , 2003, 18, 37-49.	2.9	36
173	Acute endotoxemia following transjugular intrahepatic stent-shunt insertion is associated with systemic and cerebral vasodilatation with increased whole body nitric oxide production in critically ill cirrhotic patients. <i>Journal of Hepatology</i> , 2011, 54, 265-271.	3.7	36
174	Acute-on-Chronic Liver Failure: Recent Concepts. <i>Journal of Clinical and Experimental Hepatology</i> , 2015, 5, 81-85.	0.9	36
175	Significant reduction in heart rate variability is a feature of acute decompensation of cirrhosis and predicts 90-day mortality. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 568-579.	3.7	36
176	New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, S14-S26.	3.7	36
177	Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. <i>Journal of Hepatology</i> , 2016, 65, 914-920.	3.7	35
178	Understanding hepatic encephalopathy. <i>Intensive Care Medicine</i> , 2018, 44, 231-234.	8.2	35
179	Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding. <i>Journal of Hepatology</i> , 2021, 74, 66-79.	3.7	35
180	Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis. <i>Journal of Hepatology</i> , 2003, 38, 44-50.	3.7	34

#	ARTICLE	IF	CITATIONS
181	Liver failure: basis of benefit of therapy with the molecular adsorbents recirculating system. <i>International Journal of Biochemistry and Cell Biology</i> , 2003, 35, 1306-1311.	2.8	34
182	Interorgan ammonia, glutamate, and glutamine trafficking in pigs with acute liver failure. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, G373-G381.	3.4	34
183	Mechanism of cell death in acute-on-chronic liver failure: a clinicopathologic biomarker study. <i>Liver International</i> , 2015, 35, 2564-2574.	3.9	34
184	Extracorporeal liver support devices for listed patients. <i>Liver Transplantation</i> , 2016, 22, 839-848.	2.4	34
185	Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis. <i>Medical Hypotheses</i> , 2018, 113, 91-97.	1.5	34
186	Patients with severe acute-on-chronic liver failure are disadvantaged by model for end-stage liver disease-based organ allocation policy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1204-1213.	3.7	34
187	Is minimal hepatic encephalopathy completely reversible following liver transplantation?. <i>Liver Transplantation</i> , 2004, 10, 84-87.	2.4	33
188	Clinical and Pathophysiological Consequences of Alterations in the Microbiome in Cirrhosis. <i>American Journal of Gastroenterology</i> , 2015, 110, 1399-1410.	0.4	33
189	Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality. <i>Hepatology</i> , 2021, 73, 1932-1944.	7.3	33
190	SARS-CoV-2 infection and liver involvement. <i>Hepatology International</i> , 2022, 16, 755-774.	4.2	33
191	Kidney plays a major role in ammonia homeostasis after portosystemic shunting in patients with cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, G189-G194.	3.4	32
192	Effective albumin concentration and cirrhosis mortality: From concept to reality. <i>Journal of Hepatology</i> , 2013, 59, 918-920.	3.7	32
193	A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2018, 8, 224-234.	0.9	32
194	Recombinant Alkaline Phosphatase Prevents Acute on Chronic Liver Failure. <i>Scientific Reports</i> , 2020, 10, 389.	3.3	32
195	Acute liver failure: liver support therapies. <i>Current Opinion in Critical Care</i> , 2007, 13, 215-221.	3.2	31
196	How to diagnose and manage hepatic encephalopathy. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 146-152.	1.6	31
197	Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 1116-1127.	3.7	31
198	Acute-on-chronic liver failure. <i>Clinical Medicine</i> , 2020, 20, 501-504.	1.9	31

#	ARTICLE	IF	CITATIONS
199	Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF. <i>Journal of Hepatology</i> , 2022, 77, 1325-1338.	3.7	31
200	Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. <i>Quality of Life Research</i> , 2018, 27, 1513-1520.	3.1	30
201	Gap junctions in liver disease: Implications for pathogenesis and therapy. <i>Journal of Hepatology</i> , 2019, 70, 759-772.	3.7	30
202	Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality. <i>Journal of Hepatology</i> , 2021, 74, 1355-1361.	3.7	30
203	Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation. <i>Journal of Hepatology</i> , 2021, 75, S178-S190.	3.7	30
204	Circulating microRNAs Reveal Time Course of Organ Injury in a Porcine Model of Acetaminophen-Induced Acute Liver Failure. <i>PLoS ONE</i> , 2015, 10, e0128076.	2.5	29
205	Hypothermia in Acute Liver Failure. <i>Metabolic Brain Disease</i> , 2004, 19, 215-221.	2.9	27
206	Neurological complications of acute liver failure: Pathophysiological basis of current management and emerging therapies. <i>Neurochemistry International</i> , 2012, 60, 736-742.	3.8	27
207	A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic <i>Lactobacillus casei</i> Shirota in Stable Cirrhotic Patients. <i>Nutrients</i> , 2020, 12, 1651.	4.1	27
208	Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease. <i>Hepatology</i> , 2017, 65, 1306-1318.	7.3	26
209	The impact of rifaximin on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS). <i>Frontline Gastroenterology</i> , 2017, 8, 243-251.	1.8	26
210	Systemic and regional haemodynamics in pigs with acute liver failure and the effect of albumin dialysis. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 1350-1360.	1.5	25
211	A reproducible, clinically relevant, intensively managed, pig model of acute liver failure for testing of therapies aimed to prolong survival. <i>Liver International</i> , 2013, 33, 544-551.	3.9	25
212	Characterisation of temporal microglia and astrocyte immune responses in bile duct-ligated rat models of cirrhosis. <i>Liver International</i> , 2014, 34, 1184-1191.	3.9	25
213	Acute Liver Failure: a Review. <i>Clinics in Liver Disease</i> , 2006, 10, 239-258.	2.1	24
214	Short-term abstinence from alcohol and changes in cardiovascular risk factors, liver function tests and cancer-related growth factors: a prospective observational study. <i>BMJ Open</i> , 2018, 8, e020673.	1.9	24
215	Liver Replacement Therapy. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 70-79.	2.1	23
216	Acute-on-Chronic Liver Failure: A Distinct Clinical Condition. <i>Seminars in Liver Disease</i> , 2016, 36, 107-108.	3.6	23

#	ARTICLE	IF	CITATIONS
217	Heretical thoughts into hepatic encephalopathy. <i>Journal of Hepatology</i> , 2022, 77, 539-548.	3.7	23
218	Induction of cerebral hyperemia by ammonia plus endotoxin: Does hyperammonemia unlock the blood-brain barrier?. <i>Journal of Hepatology</i> , 2007, 47, 168-171.	3.7	22
219	The brain in acute on chronic liver failure. <i>Metabolic Brain Disease</i> , 2014, 29, 965-973.	2.9	22
220	Plasma cytokine concentrations in dogs with a congenital portosystemic shunt. <i>Veterinary Journal</i> , 2014, 200, 197-199.	1.7	22
221	Modification in CSF specific gravity in acutely decompensated cirrhosis and acute on chronic liver failure independent of encephalopathy, evidences for an early blood-CSF barrier dysfunction in cirrhosis. <i>Metabolic Brain Disease</i> , 2017, 32, 369-376.	2.9	22
222	Quality of life measures predict mortality in patients with cirrhosis and severe ascites. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 321-330.	3.7	22
223	The role of RIPK1 mediated cell death in acute on chronic liver failure. <i>Cell Death and Disease</i> , 2022, 13, 5.	6.3	22
224	Mechanisms of changes in renal handling of sodium following transjugular intrahepatic portal systemic stent-shunt (TIPSS). <i>European Journal of Gastroenterology and Hepatology</i> , 1996, 8, 1111-1116.	1.6	21
225	Transjugular intrahepatic portosystemic stent-shunt (TIPSS) insertion as a prelude to orthotopic liver transplantation in patients with severe portal hypertension. <i>European Journal of Gastroenterology and Hepatology</i> , 1996, 8, 1145-1149.	1.6	21
226	Impact of transjugular intrahepatic portosystemic stent-shunt for secondary prophylaxis of oesophageal variceal haemorrhage: a single-centre study over an 11-year period. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 615-626.	1.6	21
227	Early transplantation maximizes survival in severe acute-on-chronic liver failure: Results of a Markov decision process model. <i>JHEP Reports</i> , 2021, 3, 100367.	4.9	21
228	Extracorporeal albumin dialysis in acute-on-chronic liver failure: Will it stand the test of time?. <i>Hepatology</i> , 2002, 36, 1014-1016.	7.3	20
229	Transjugular intrahepatic portosystemic stent-shunt in the management of gastric and ectopic varices. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1155-1160.	1.6	20
230	Pharmacotherapy for hyperammonemia. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1685-1695.	1.8	20
231	Caval Subtraction 2D Phase-Contrast MRI to Measure Total Liver and Hepatic Arterial Blood Flow. <i>Investigative Radiology</i> , 2017, 52, 170-176.	6.2	20
232	â€˜Equityâ€™ and â€˜Justiceâ€™ for patients with acute-on chronic liver failure: A call to action. <i>Journal of Hepatology</i> , 2021, 75, 1228-1235.	3.7	20
233	A PILOT STUDY OF INDOCYANINE GREEN CLEARANCE AS AN EARLY PREDICTOR OF GRAFT FUNCTION. <i>Transplantation</i> , 1994, 58, 196-199.	1.0	19
234	MARS: A new treatment for hepatorenal failure. <i>Gastroenterology</i> , 2000, 119, 1799-1800.	1.3	19

#	ARTICLE	IF	CITATIONS
235	The puzzle of endothelial nitric oxide synthase dysfunction in portal hypertension: The missing piece?. <i>Hepatology</i> , 2007, 46, 943-946.	7.3	19
236	Role of artificial liver support in hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2009, 24, 15-26.	2.9	19
237	Association between hepatic histopathologic lesions and clinical findings in dogs undergoing surgical attenuation of a congenital portosystemic shunt: 38 cases (2000â€”2004). <i>Journal of the American Veterinary Medical Association</i> , 2011, 239, 638-645.	0.5	19
238	Mechanistic biomarkers in acute liver injury: Are we there yet?. <i>Journal of Hepatology</i> , 2012, 56, 1003-1005.	3.7	19
239	Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 533-541.	1.9	19
240	L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetyl-glycine formation: a novel ammonia-lowering pathway. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G1024-G1031.	3.4	19
241	Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. <i>Critical Care</i> , 2017, 21, 321.	5.8	19
242	Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation. <i>Scientific Reports</i> , 2022, 12, 3418.	3.3	19
243	Systemic and regional changes in plasma endothelin following transient increase in portal pressure. <i>Liver Transplantation</i> , 2003, 9, 32-39.	2.4	18
244	Treatment of Hyperammonemia in Liver Failure: A Tale of Two Enzymes. <i>Gastroenterology</i> , 2009, 136, 2048-2051.	1.3	18
245	Extracorporeal Liver Support. <i>Blood Purification</i> , 2012, 34, 158-163.	1.8	18
246	Acute changes in cerebral blood flow and metabolism during portosystemic shunting. <i>Liver Transplantation</i> , 2001, 7, 274-278.	2.4	17
247	Nitric oxide and l-arginine metabolism in a devascularized porcine model of acute liver failure. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G435-G441.	3.4	17
248	The gut is a key target of therapy in hepatic encephalopathy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 7-8.	17.8	17
249	Primary prophylaxis of variceal bleeding in cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 349-358.	1.6	16
250	Arterial ammonia levels in cirrhosis are determined by systemic and hepatic hemodynamics, and by organ function a quantitative modelling study. <i>Liver International</i> , 2014, 34, e45-55.	3.9	16
251	Attenuation of Congenital Portosystemic Shunt Reduces Inflammation in Dogs. <i>PLoS ONE</i> , 2015, 10, e0117557.	2.5	16
252	Development of an organ failure score in acute liver failure for transplant selection and identification of patients at high risk of fatality. <i>PLoS ONE</i> , 2017, 12, e0188151.	2.5	16

#	ARTICLE	IF	CITATIONS
253	Infliximab and alcoholic hepatitis. <i>Hepatology</i> , 2004, 40, 499-500.	7.3	15
254	Interorgan metabolism of ornithine phenylacetate (OP) – A novel strategy for treatment of hyperammonemia. <i>Biochemical Pharmacology</i> , 2013, 85, 115-123.	4.4	15
255	Treatment of hyperammonemia in liver failure. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2013, 17, 1.	2.5	15
256	Caecal ligation and puncture induced sepsis in the rat results in increased brain water content and perimicrovessel oedema. <i>Metabolic Brain Disease</i> , 2014, 29, 837-843.	2.9	15
257	Novel insights into ammonia-mediated neurotoxicity pointing to potential new therapeutic strategies. <i>Hepatology</i> , 2014, 60, 1101-1103.	7.3	15
258	Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure. <i>JHEP Reports</i> , 2021, 3, 100355.	4.9	15
259	Endotoxin measures in patients' sample: How valid are the results?. <i>Journal of Hepatology</i> , 2007, 47, 726-727.	3.7	14
260	Acute-on-chronic liver failure: an early biopsy is essential?. <i>Gut</i> , 2010, 59, 1455-1456.	12.1	14
261	Rifaximin in hepatic encephalopathy: More than just a non-absorbable antibiotic?. <i>Journal of Hepatology</i> , 2010, 53, 580-582.	3.7	14
262	Long-term outcome in patients with acute liver failure. <i>Liver International</i> , 2018, 38, 2228-2238.	3.9	14
263	Hypothermia for the management of intracranial hypertension in acute liver failure. <i>Metabolic Brain Disease</i> , 2002, 17, 437-444.	2.9	13
264	Hepatic guanylate cyclase activity is decreased in a model of cirrhosis: A quantitative cytochemistry study. <i>FEBS Letters</i> , 2006, 580, 2123-2128.	2.8	13
265	Acute-on-chronic liver failure: from concept to a new syndrome. <i>Current Opinion in Critical Care</i> , 2011, 17, 152.	3.2	13
266	Metabolism and Effects on Endogenous Metabolism of Paracetamol (Acetaminophen) in a Porcine Model of Liver Failure. <i>Toxicological Sciences</i> , 2020, 175, 87-97.	3.1	13
267	Recent advances in understanding and managing hepatic encephalopathy in chronic liver disease. <i>F1000Research</i> , 2020, 9, 312.	1.6	13
268	Abnormal brain oxygen homeostasis in an animal model of liver disease. <i>JHEP Reports</i> , 2022, , 100509.	4.9	13
269	The role of the Molecular Adsorbents Recirculating System (MARS) in the management of liver failure. <i>Perfusion (United Kingdom)</i> , 2004, 19, S43-S48.	1.0	12
270	Gc-globulin to predict outcome in acute liver failure: A panacea?. <i>Liver Transplantation</i> , 2005, 11, 1169-1171.	2.4	12



#	ARTICLE	IF	CITATIONS
271	Ornithine phenylacetate revisited. <i>Metabolic Brain Disease</i> , 2013, 28, 327-331.	2.9	12
272	Cracking the ENCODE: From transcription to therapeutics. <i>Hepatology</i> , 2013, 57, 2532-2535.	7.3	12
273	Expression of TLR-2 in hepatocellular carcinoma is associated with tumour proliferation, angiogenesis and Caspase-3 expression. <i>Pathology Research and Practice</i> , 2020, 216, 152980.	2.3	12
274	Acute and Chronic Liver Failure: A New Disease or an Old One Hiding in Plain Sight?. <i>Clinical Liver Disease</i> , 2020, 15, S45-S51.	2.1	12
275	Treatment of hepatic encephalopathy: It's not lactulose. <i>BMJ: British Medical Journal</i> , 2004, 329, 112.1.	2.3	12
276	Hyperammonaemia induces mitochondrial dysfunction and neuronal cell death. <i>JHEP Reports</i> , 2022, 4, 100510.	4.9	12
277	In vivo hepatic magnetic resonance spectroscopy: clinical or research tool?. <i>Journal of Hepatology</i> , 1996, 25, 414-424.	3.7	11
278	Hypothermia for the management of intracranial hypertension in acute liver failure. <i>Current Opinion in Critical Care</i> , 2001, 7, 257-262.	3.2	11
279	Pros and cons of L-arginine supplementation in disease. <i>Nutrition Research Reviews</i> , 2004, 17, 193-210.	4.1	11
280	The impact of obesity in cirrhotic patients with septic shock: A retrospective cohort study. <i>Liver International</i> , 2018, 38, 1230-1241.	3.9	11
281	Acute and Chronic Liver Failure: A Distinct Clinical Syndrome That Has Reclassified Cirrhosis. <i>Clinical Liver Disease</i> , 2019, 14, 171-175.	2.1	11
282	Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute and chronic liver failure and acute decompensation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 240-248.	2.8	11
283	Protein synthesis is severely diminished following a simulated upper GI bleed in patients with cirrhosis. <i>Journal of Hepatology</i> , 2008, 49, 726-731.	3.7	10
284	Plasma Lipid Profiling in a Rat Model of Hepatocellular Carcinoma: Potential Modulation Through Quinolone Administration. <i>Journal of Clinical and Experimental Hepatology</i> , 2015, 5, 286-294.	0.9	10
285	MELD remains the best predictor of mortality in outpatients with cirrhosis and severe ascites. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 492-499.	3.7	10
286	Genetic variants of innate immunity receptors are associated with mortality in cirrhotic patients with bacterial infection. <i>Liver International</i> , 2020, 40, 646-653.	3.9	10
287	Correlation of the Intracranial Pressure to the Central Venous Pressure in the Late Phase of Acute Liver Failure in a Porcine Model. <i>Acta Neurochirurgica Supplementum</i> , 2012, 114, 387-391.	1.0	10
288	Diagnosis of hepatic encephalopathy: Will in vivo proton MRS play a role?. <i>Hepatology</i> , 1999, 29, 1605-1607.	7.3	9

#	ARTICLE	IF	CITATIONS
289	To pee or not to pee. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 449-454.	1.6	9
290	Brain lactate in hepatic encephalopathy: Friend or foe?. <i>Journal of Hepatology</i> , 2014, 60, 476-477.	3.7	9
291	Corrigendum to "Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites" [ <i>Hepatology</i> 2015;62:968-974]. <i>Journal of Hepatology</i> , 2015, 63, 290.	3.7	9
292	Continuous low flow ascites drainage through the urinary bladder via the Alfapump system in palliative patients with malignant ascites. <i>BMC Palliative Care</i> , 2019, 18, 109.	1.8	9
293	Long-Term Outcomes of Everolimus Therapy in De Novo Liver Transplantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Transplantation Proceedings</i> , 2021, 53, 148-158.	0.6	9
294	BIO-ARTIFICIAL LIVER SUPPORT FOR ACUTE LIVER FAILURE: SHOULD WE BE USING IT TO TREAT PATIENTS?. <i>Transplantation</i> , 2002, 73, 165-166.	1.0	9
295	Shunt insufficiency after TIPSS. <i>CardioVascular and Interventional Radiology</i> , 1998, 21, 187-188.	2.0	8
296	Reply to: "Is a liver biopsy necessary in alcoholic hepatitis?". <i>Journal of Hepatology</i> , 2012, 56, 1428-1429.	3.7	8
297	Hepatic encephalopathy: New treatments. <i>Clinical Liver Disease</i> , 2015, 5, 109-111.	2.1	8
298	Organ allocation for patients with acute-on-chronic liver failure: Time to look beyond MELD-sodium?. <i>Journal of Hepatology</i> , 2020, 73, 1316-1318.	3.7	8
299	Primary biliary cholangitis has the highest waitlist mortality in patients with cirrhosis and acute on chronic liver failure awaiting liver transplant. <i>Clinical Transplantation</i> , 2021, 35, e14479.	1.6	8
300	Overt hepatic encephalopathy is an independent risk factor for de novo infection in cirrhotic patients with acute decompensation. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, , .	3.7	8
301	Alcohol and Acute-on-Chronic Liver Failure. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1360-1370.	0.9	8
302	Fatty Hepatocytes Induce Skeletal Muscle Atrophy In Vitro: A New 3D Platform to Study the Protective Effect of Albumin in Non-Alcoholic Fatty Liver. <i>Biomedicines</i> , 2022, 10, 958.	3.2	8
303	Urotensin II: better than somatostatin for portal hypertension?. <i>Hepatology</i> , 2003, 31, 1201-1202.	7.3	7
304	A multi-journal partnership to highlight joint first-authors of manuscripts. <i>Gut</i> , 2015, 64, 189-189.	12.1	7
305	Novel approaches and therapeutics in acute-on-chronic liver failure. <i>Liver Transplantation</i> , 2016, 22, 14-19.	2.4	7
306	From the Editor's desk..... <i>Journal of Hepatology</i> , 2016, 64, 1-4.	3.7	7

#	ARTICLE	IF	CITATIONS
307	Neurocritical Care Management of Hepatic Encephalopathy and Coma in Liver Failure. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 523-537.	2.1	7
308	Reversal of severe cholestasis caused by chronic graft-versus-host disease with the MARS liver-support device. <i>Transplantation</i> , 2003, 75, 1766-1767.	1.0	6
309	Blood-brain barrier in liver failure: are cracks appearing in the wall?. <i>Liver International</i> , 2010, 30, 1087-1090.	3.9	6
310	Journal of Hepatology: The home of liver research. <i>Journal of Hepatology</i> , 2015, 62, 1-3.	3.7	6
311	Not All Mice Are the Same: Standardization of Animal Research Data Presentation. <i>Gut</i> , 2016, 65, 894-895.	12.1	6
312	Hypercoagulability progresses to hypocoagulability during evolution of acetaminophen-induced acute liver injury in pigs. <i>Scientific Reports</i> , 2017, 7, 9347.	3.3	6
313	Portosystemic Shunt Embolization and Recurrent Ascites: A Single-Center Case Series. <i>Gastroenterology</i> , 2018, 155, 1649-1650.	1.3	6
314	The Macrophage Activation Marker Soluble CD163 is Associated With Early Allograft Dysfunction After Liver Transplantation. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 302-311.	0.9	6
315	Inhibition of TLR7 and TLR9 Reduces Human Cholangiocarcinoma Cell Proliferation and Tumor Development. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1806-1821.	2.3	6
316	Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 1756284819879565.	3.2	6
317	Transjugular intrahepatic portosystemic stent-shunt insufficiency and the role of diabetes mellitus. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 257-261.	1.6	5
318	Should a biopsy precede liver resection or transplantation for presumed hepatocellular carcinoma when the alfa fetoprotein is normal?. <i>Transplantation</i> , 2004, 77, 637-638.	1.0	5
319	Overnight glucose infusion suppresses renal ammoniogenesis and reduces hyperammonaemia induced by a simulated bleed in cirrhotic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 921-928.	3.7	5
320	Emerging trends in hepatology: 30years of the <i>Journal of Hepatology</i> and 50years of EASL. <i>Journal of Hepatology</i> , 2015, 62, S1-S3.	3.7	5
321	Lipopolysaccharide-Induced Neutrophil Dysfunction Following Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS) Insertion is Associated with Organ Failure and Mortality. <i>Scientific Reports</i> , 2017, 7, 40157.	3.3	5
322	From the Editor's desk.... <i>Journal of Hepatology</i> , 2017, 67, 1-4.	3.7	5
323	Reply. <i>Gastroenterology</i> , 2019, 157, 1163-1164.	1.3	5
324	Update on extracorporeal liver support. <i>Current Opinion in Critical Care</i> , 2020, 26, 1.	3.2	5

#	ARTICLE	IF	CITATIONS
325	A Call for Randomization in Clinical Trials of Liver Machine Perfusion Preservation. <i>Hepatology</i> , 2021, 73, 2586-2591.	7.3	5
326	Consensus care recommendations for alfapump® in cirrhotic patients with refractory or recurrent ascites. <i>BMC Gastroenterology</i> , 2022, 22, 111.	2.0	5
327	Gastric mucosal bleeding time in cirrhosis. <i>Gastrointestinal Endoscopy</i> , 1994, 40, 599-602.	1.0	4
328	Is Gilbert's the culprit in indinavir-induced hyperbilirubinemia?. <i>Hepatology</i> , 2002, 35, 1269-1270.	7.3	4
329	Treatment of hepatic encephalopathy. <i>Lancet, The</i> , 2005, 365, 1385-1386.	13.7	4
330	Alcohol takes the toll on immune function. <i>Liver International</i> , 2010, 30, 934-936.	3.9	4
331	Diagnosis and Treatment of Low-Grade Hepatic Encephalopathy. <i>Digestive Diseases</i> , 2015, 33, 562-569.	1.9	4
332	Erroneous Ammonia Measurement is Not Synonymous With a Lack of Efficacy of Ammonia-Lowering Therapies in Hepatic Encephalopathy. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2456-2457.	4.4	4
333	The "Alter Ego" of Albumin in Cirrhosis. <i>Hepatology</i> , 2021, 74, 1734-1736.	7.3	4
334	Prognostic Role of Liver Biopsy in Patients With Severe Indeterminate Acute Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1130-1141.e7.	4.4	4
335	High-risk liver transplant recipients with grade 3 acute on chronic liver failure should receive the good quality graft. <i>Liver International</i> , 2022, 42, 1629-1637.	3.9	4
336	Ideal hepatocyte: Quest for the Holy Grail. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1-4.	2.8	3
337	From the Editor's desk..... <i>Journal of Hepatology</i> , 2015, 63, 1-4.	3.7	3
338	Mathematical Model of Ammonia Handling in the Rat Renal Medulla. <i>PLoS ONE</i> , 2015, 10, e0134477.	2.5	3
339	Pulmonary vascular clearance of harmful endogenous macromolecules in a porcine model of acute liver failure. <i>Annals of Hepatology</i> , 2016, 15, 427-435.	1.5	3
340	PS-149-Recombinant glutamine synthetase: A novel strategy for the treatment of hyperammonemia and consequent hepatic encephalopathy in rodent model of cirrhosis and urea cycle enzyme deficiency. <i>Journal of Hepatology</i> , 2019, 70, e93-e94.	3.7	3
341	The analysis of acetaminophen (paracetamol) and seven metabolites in rat, pig and human plasma by U(H)PLC-MS. <i>Bioanalysis</i> , 2020, 12, 485-500.	1.5	3
342	Validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis. <i>Journal of Hepatology</i> , 2022, 76, 485-487.	3.7	3

#	ARTICLE	IF	CITATIONS
343	Rapid Pathogen Detection for Infected Ascites in Cirrhosis using Metagenome Next-Generation Sequencing: A Case Series. <i>Liver International</i> , 2021, , .	3.9	3
344	There Is a Great Future in Plastics: Personalized Approach to the Management of Hilar Cholangiocarcinoma Using a 3-D-Printed Liver Model. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2210-2215.	2.3	3
345	Endotoxemia during liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 1616-1617.	2.4	2
346	Albumin Regeneration for Extracorporeal Liver Support Using Prometheus: A Step in the Right Direction. <i>Gastroenterology</i> , 2012, 142, 690-692.	1.3	2
347	Reply to: "Acute-on-chronic liver failure" Its definition remains unclear. <i>Journal of Hepatology</i> , 2013, 59, 191.	3.7	2
348	Early Increase in Ammonia Is A Feature of Non-Alcoholic Fatty Liver Disease and the Ammonia Lowering Drug, Ornithine Phenylacetate (OCR002) Prevents Progression of Fibrosis in A Rodent Model. <i>Journal of Clinical and Experimental Hepatology</i> , 2017, 7, S73-S74.	0.9	2
349	Editorial: alfapump"an alternative to large-volume paracentesis for patients with refractory ascites?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 139-140.	3.7	2
350	New concepts and perspectives in decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, S1-S2.	3.7	2
351	Judging the value of ammonia measurement on lactulose dosing: Apples and oranges?. <i>Canadian Liver Journal</i> , 2021, 4, 72-74.	0.9	2
352	Waitlist Priority for Patients with Acute-on-Chronic Liver Failure: Not Just Horseplay. <i>Liver Transplantation</i> , 2022, 28, 539-543.	2.4	2
353	Congenital glutamine deficiency with glutamine synthetase mutations. <i>New England Journal of Medicine</i> , 2006, 354, 1093-4; author reply 1093-4.	27.0	2
354	Intrinsic renal disease in cirrhosis: adding insult to injury. <i>Liver International</i> , 2010, 30, 639-641.	3.9	1
355	Reply to: "The quest for the elusive factors that underpin neutrophil dysfunction in cirrhosis goes on". <i>Journal of Hepatology</i> , 2012, 56, 1213-1214.	3.7	1
356	Activation of farnesoid X receptor (FXR) by its agonist int-747 restores hepatic endothelial NOS activity and lowers portal pressure in cirrhotic rats by modulating the DDAH-ADMA pathway. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, S11.	0.9	1
357	Joan Cordoba Cordona (1964-2014): A dedicated clinician, great scientist, mentor, friend, collaborator, critic. <i>Journal of Hepatology</i> , 2014, 60, 1105-1107.	3.7	1
358	Obeticholic acid, a Farnesoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. <i>Hepatology</i> , 2014, 60, 1798-1799.	7.3	1
359	From the Editor's desk. <i>Journal of Hepatology</i> , 2016, 65, 457-461.	3.7	1
360	<i>Journal of Hepatology</i> , 2016. <i>Journal of Hepatology</i> , 2016, 64, 5-7.	3.7	1

#	ARTICLE	IF	CITATIONS
361	From the Editor's desk.... Journal of Hepatology, 2017, 66, 1107-1110.	3.7	1
362	Novel therapies in the management of acute episodes of hepatic encephalopathy. Clinical Liver Disease, 2017, 9, 66-68.	2.1	1
363	From the Editor's desk..... Journal of Hepatology, 2017, 66, 671-674.	3.7	1
364	Non selective beta-blocker in cirrhosis: not "whether" but "who and how". AME Medical Journal, 0, 2, 90-90.	0.4	1
365	From the Editor's desk.... Journal of Hepatology, 2018, 68, 1107-1109.	3.7	1
366	From the Editor's desk..... Journal of Hepatology, 2018, 69, 265-268.	3.7	1
367	Non-selective beta blockers in cirrhosis: time to extend the indications?. Annals of Translational Medicine, 2019, 7, S355-S355.	1.7	1
368	Journal of Hepatology: The Home of Liver Research, 2015"2019. Journal of Hepatology, 2019, 71, 1065-1069.	3.7	1
369	Occupational hazard in an immunosuppressed patient. Frontline Gastroenterology, 2021, 12, 74-76.	1.8	1
370	Potential novel approaches to prevent the risk of infection in patients with variceal bleeding. Journal of Hepatology, 2021, , .	3.7	1
371	Porcine model characterizing various parameters assessing the outcome after acetaminophen intoxication induced acute liver failure. World Journal of Gastroenterology, 2017, 23, 1576.	3.3	1
372	The Lipopolysaccharide-Sensing Caspase(s)-4/11 Are Activated in Cirrhosis and Are Causally Associated With Progression to Multi-Organ Injury. Frontiers in Cell and Developmental Biology, 2021, 9, 668459.	3.7	1
373	Presence of multilobular necrosis on liver biopsy identifies corticosteroid responsiveness in acute indeterminate hepatitis. Liver International, 2021, , .	3.9	1
374	Severe alcoholic hepatitis as precipitant for organ failure and ACLF. Zeitschrift Fur Gastroenterologie, 2022, 60, 67-76.	0.5	1
375	Use of Non-selective Beta blockers in Decompensated Cirrhosis and ACLF. Current Hepatology Reports, 2022, 21, 29-36.	0.9	1
376	A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. European Journal of Gastroenterology and Hepatology, 1998, 10, 100.	1.6	0
377	Combined Hepatic Artery and Segmental Portal Vein Occlusion in Antiphospholipid Syndrome. Digestive Surgery, 2000, 17, 405-406.	1.2	0
378	Extracorporeal albumin dialysis in acute-on-chronic liver failure: Will it stand the test of time?. Hepatology, 2002, 36, 1014-1016.	7.3	0

#	ARTICLE	IF	CITATIONS
379	Decompensation of chronic stable alcoholic liver disease by severe exfoliative dermatitis. European Journal of Gastroenterology and Hepatology, 2003, 15, 433-435.	1.6	0
380	'Nipped in the Budd'. European Journal of Gastroenterology and Hepatology, 2005, 17, 65-68.	1.6	0
381	Liver Failure and Intracerebral Hypertension. , 2005, , 179-190.		0
382	Probiotics for patients with liver cirrhosis: Reply. Journal of Hepatology, 2008, 49, 1081-1082.	3.7	0
383	When to use renal replacement therapy and bioartificial support for renal failure in patients with cirrhosis. Clinical Liver Disease, 2013, 2, 116-119.	2.1	0
384	An exciting time for Hepatology. Liver International, 2013, 33, 2-3.	3.9	0
385	â€Hepatologyâ€™ on the move. Liver International, 2014, 34, 820-821.	3.9	0
386	From the Editorâ€™s desk.... Journal of Hepatology, 2015, 63, 1057-1061.	3.7	0
387	From the Editorâ€™s desk.... Journal of Hepatology, 2015, 63, 1299-1302.	3.7	0
388	From the Editorâ€™s deskâ€¦. Journal of Hepatology, 2015, 62, 991-994.	3.7	0
389	From the Editorâ€™s desk.... Journal of Hepatology, 2015, 63, 537-539.	3.7	0
390	From the Editorâ€™s desk.... Journal of Hepatology, 2016, 64, 1199-1202.	3.7	0
391	From the Editorâ€™s desk.... Journal of Hepatology, 2016, 65, 233-236.	3.7	0
392	Reply to: â€Non-selective beta-blockers for the patients with acute on chronic liver failureâ€: Journal of Hepatology, 2016, 65, 646.	3.7	0
393	From the Editorâ€™s desk.... Journal of Hepatology, 2016, 65, 657-660.	3.7	0
394	From the Editorâ€™s desk.... Journal of Hepatology, 2016, 64, 991-995.	3.7	0
395	From the Editorâ€™s desk.... Journal of Hepatology, 2016, 64, 253-256.	3.7	0
396	Reply to â€Keep the sick from harm in spontaneous bacterial peritonitis: Dose of beta blockers mattersâ€: Journal of Hepatology, 2016, 64, 1456-1457.	3.7	0

#	ARTICLE	IF	CITATIONS
397	From the Editor's desk..... Journal of Hepatology, 2017, 66, 263-266.	3.7	0
398	Short article. European Journal of Gastroenterology and Hepatology, 2017, 29, 535-538.	1.6	0
399	From the Editor's desk.... Journal of Hepatology, 2017, 66, 469-472.	3.7	0
400	From the Editor's desk.... Journal of Hepatology, 2017, 67, 437-440.	3.7	0
401	From the Editor's desk.... Journal of Hepatology, 2017, 67, 207-210.	3.7	0
402	From the Editor's desk.... Journal of Hepatology, 2017, 67, 1125-1128.	3.7	0
403	From the Editor's desk..... Journal of Hepatology, 2018, 68, 631-634.	3.7	0
404	From the Editor's Desk. Journal of Hepatology, 2018, 69, 759-761.	3.7	0
405	From the Editor's desk..... Journal of Hepatology, 2018, 69, 993-995.	3.7	0
406	Corrigendum to "From the Editor's Desk August 2018" [J Hepatol 69 (2018) 265-268]. Journal of Hepatology, 2018, 69, 987.	3.7	0
407	Reply to: "Obesity a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis". Journal of Hepatology, 2018, 69, 758.	3.7	0
408	From the Editor's desk. Journal of Hepatology, 2019, 71, 231-234.	3.7	0
409	PS-101-Inhibition of toll-like receptor 4 using TAK-242 is a novel therapy for prevention and treatment of acute-on-chronic liver failure. Journal of Hepatology, 2019, 70, e64-e65.	3.7	0
410	FRI-308-Inhibition of alpha 2A adrenergic receptors reduces liver inflammation in experimental NASH. Journal of Hepatology, 2019, 70, e531-e532.	3.7	0
411	Editorial: The Role of Myeloid-Derived Cells in the Progression of Liver Disease. Frontiers in Immunology, 2019, 10, 2208.	4.8	0
412	From the Editor's Desk. Journal of Hepatology, 2019, 71, 641-644.	3.7	0
413	From the Editor's desk. Journal of Hepatology, 2019, 71, 1-4.	3.7	0
414	FRI-115-Toll-like receptor 4: A novel therapeutic target for the treatment of hyperammonemia. Journal of Hepatology, 2019, 70, e437-e438.	3.7	0



#	ARTICLE	IF	CITATIONS
415	Reply. Hepatology, 2019, 70, 1084-1085.	7.3	0
416	From the Editor's desk. Journal of Hepatology, 2019, 70, 583-586.	3.7	0
417	From the Editor's desk. Journal of Hepatology, 2019, 70, 819-821.	3.7	0
418	FRI-084-Targeting Toll-Like Receptor 4 signalling with TAK-242: A novel therapy for acute liver failure. Journal of Hepatology, 2019, 70, e421.	3.7	0
419	From the Editor's desk..... Journal of Hepatology, 2019, 70, 335-338.	3.7	0
420	Wide variations in liver transplantation (LT) policies across Europe for patients with acute-on-chronic liver failure (ACLF) despite excellent post-LT survival: Results of a CLIF/ELITA collaborative study. Journal of Hepatology, 2020, 73, S126-S127.	3.7	0
421	EASL Recognition Award Recipient 2020: Prof. Roger Williams. Journal of Hepatology, 2020, 73, 479-481.	3.7	0
422	Share MELD-35 does not fully address the high waiting list mortality of patients with acute on chronic liver failure grade 3. Journal of Hepatology, 2020, 73, S8-S9.	3.7	0
423	Hepatocytes undergo pyroptosis in response to lipopolysaccharide exposure, and can be sensitised to cell death by ER stress. Journal of Hepatology, 2020, 73, S214-S215.	3.7	0
424	Recombinant glutamine synthetase (AM-535): a novel therapeutic approach for the treatment of hyperammonaemia and its deleterious effects on multiple systems. Journal of Hepatology, 2020, 73, S454-S455.	3.7	0
425	Cognitive dysfunction occurs early in experimentally induced NAFLD and is associated with systemic inflammation. Journal of Hepatology, 2020, 73, S668-S669.	3.7	0
426	Refining the renal failure criteria of the EASL-CLIF diagnostic model for defining acute-on-chronic liver failure (ACLF). Journal of Hepatology, 2020, 73, S497.	3.7	0
427	Reply to: "Failure to control variceal bleeding: Definition matters". Journal of Hepatology, 2021, 74, 1492-1493.	3.7	0
428	What Role Should Acute-on-Chronic Liver Failure Play in Liver Transplant Prioritization? A Survey of US-Based Transplant Providers. Liver Transplantation, 2021, 27, 1219-1220.	2.4	0
429	P098...CirroCare®-a pilot study of digital home management of advanced cirrhosis to determine feasibility and utility to diagnose new decompensation events. , 2021, , ,		0
430	Defining the prognosis of critically ill patients with alcohol-related liver disease. Journal of Hepatology, 2021, 75, 986-987.	3.7	0
431	Ornithine Phenylacetate: A Novel Strategy for the Treatment of Hepatic Encephalopathy. , 2012, , 165-174.		0
432	An Unusual Case of Hematochezia. Cureus, 2020, 12, e8957.	0.5	0

#	ARTICLE	IF	CITATIONS
433	Editorial: infections and hepatic encephalopathyâ€”does the chicken or the egg come first? A novel perspective at the horizon. Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 746-747.	3.7	0
434	Reply to: â€œSarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantationâ€• <i>Journal of Hepatology</i> , 2022, 76, 986.	3.7	0
435	Letter: de novo infection in hepatic encephalopathyâ€”The culprit or the victim? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1231-1232.	3.7	0
436	PRO: Patients With Acuteâ€”onâ€”Chronic Liver Failure Should Receive Priority on the Liver Transplant Waiting List. <i>Clinical Liver Disease</i> , 2022, 19, 203-206.	2.1	0